UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating and announces Price Target of $52.
UBS analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating and announces Price Target of $52.